Salute e Benessere

Uveitis Treatment Market Size is Estimated at $1.4 Billion by 2034, Growing at a…

Advanced treatment methods, which include biodegradable microspheres and intravitreal implants, provide significant advantages since they directly administer prolonged pharmaceutical exposure to the affected eye tissues. Reducing the need for repeated injections or systemic medications lowers the risk of undesirable systemic effects while increasing patient compliance and convenience. Advanced treatment methods, which include biodegradable microspheres and intravitreal implants, provide...
PR Newswire
16/07/2024

Soft N Dry Tree Free Diapers Now in European Markets

European Expansion and Compliance with EUDR European Expansion and Compliance with EUDR The entry of Soft N Dry's Tree Free disposable baby diapers into the European market marks a significant milestone for the company. Retailers inFrance,Germany, and the UK can now offer these eco-friendly products under their own house or private label brands, providing a sustainable alternative to traditional disposable diapers. This move is timely, aligning with the EU's new Deforestation-Free...
PR Newswire
16/07/2024

Esophageal Cancer Market Size to be Worth USD 4.6 billion by 2034, Growing at…

The esophageal cancer market is experiencing significant growth driven by several key factors influencing diagnosis, treatment, and research efforts globally. Esophageal cancer, a malignancy affecting the lining of the esophagus, poses substantial challenges due to its often late-stage diagnosis and aggressive nature. The market's expansion is primarily propelled by an increasing incidence of risk factors such as smoking, heavy alcohol consumption, and gastroesophageal reflux disease (GERD)…
PR Newswire
16/07/2024

Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance

Second Quarter 2024 Second Quarter 2024 Outlook 2024 - updated The strategic portfolio includes Sobi's medicines Aspaveli/Empaveli, Doptelet excludingChina, Gamifant, Vonjo and Zynlonta ®, and royalty on Sanofi's sales on Altuviiio ® and Beyfortus ®. Investors, analysts and media are invited to participate in a conference call, which will include a presentation of the results and a Q&A session on the same day at14:00 CEST. The presentation can be followed livehere...
PR Newswire
16/07/2024

EEG Devices Market is set to grow from US$ 1.7 Bn in 2024 to USD 4.7 Bn by 2034…

With the rising prevalence of neurological disorders, the necessity to employ key diagnostics methods emerges. Due to this, many medical professionals are seen to be inclined toward using efficient as well as accurate methods that can deliver optimum results. With the rising prevalence of neurological disorders, the necessity to employ key diagnostics methods emerges. Due to this, many medical professionals are seen to be inclined toward using efficient as well as accurate methods that can...
PR Newswire
16/07/2024

EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics…

Asceneuron has completed five early-stage clinical trials, showing that their treatment effectively reaches the brain and targets the OGA enzyme. Asceneuron plans to initiate its first Phase 2 clinical study later this year. Asceneuron has completed five early-stage clinical trials, showing that their treatment effectively reaches the brain and targets the OGA enzyme. Asceneuron plans to initiate its first Phase 2 clinical study later this year. Barbara Angehrn Pavik, Chief Executive...
PR Newswire
16/07/2024

Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking…

ASN51's unique mode of action and convenient oral formulation make it an ideal therapy for patients with Alzheimer's disease. Asceneuron has completed five Phase 1 clinical trials, demonstrating complete central nervous system uptake and high OGA enzyme occupancy. Asceneuron plans to initiate its first Phase 2 clinical study later this year. ASN51's unique mode of action and convenient oral formulation make it an ideal therapy for patients with Alzheimer's disease. Asceneuron has completed…
PR Newswire
16/07/2024

Novo Holdings leads $100 million Series C financing of Asceneuron to advance…

ASN51's unique mode of action and convenient oral formulation make it an ideal therapy for patients with Alzheimer's disease. Asceneuron has completed five Phase 1 clinical trials, demonstrating complete central nervous system uptake and high OGA enzyme occupancy, indicating its potential for differentiation from its competitors. Asceneuron plans to initiate its first Phase 2 clinical study later this year. ASN51's unique mode of action and convenient oral formulation make it an ideal therapy...
PR Newswire
16/07/2024

Nicox appoints experienced biotech leader Damian Marron as Chair of the Board…

Press ReleaseNicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director Damian Marron is an experienced healthcare executive, non-executive Director/Chair and advisorMarc Le Bozec is an experienced life sciences entrepreneur with a background in finance, organization and strategic consultingJean-François Labbe retires as Chair and member of the Board at the completion of his term; Les Kaplan has also decided to step...
Nasdaq GlobeNewswire
16/07/2024

SKYRIZI's Approval For Ulcerative Colitis Treatment Expands AbbVie's Portfolio…

As per DelveInsight analysis, the total ulcerative colitis diagnosed prevalent cases in the 7MM comprised approximately 3 million cases in 2023 and are projected to increase by 2034. Per analyst estimates, approximately 60% of cases accounted for moderate to severe cases of ulcerative colitis among the 7MM. As per DelveInsight analysis, the total ulcerative colitis diagnosed prevalent cases in the 7MM comprised approximately3 millioncases in 2023 and are projected to increase by 2034...
PR Newswire
15/07/2024

The Board of Directors of Sobi exercises authorisation for repurchase of shares…

Today, the Board of Directors has resolved to, conditional upon subscription and payment by Svenska Handelsbanken AB, exercise the repurchase authorisation for the said purpose by repurchasing all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 16 July – 14 November 2024. Today, the Board of Directors has resolved to, conditional upon...
PR Newswire
15/07/2024

Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition…

The strategic partnership between Photocure and Richard Wolf builds off a longstanding relationship between the two companies associated with co-promotion, disease awareness, education, market development, and clinical research. Photocure and Richard Wolf will co-promote the new blue light flexible system in the U.S., Europe and other countries globally. The strategic partnership between Photocure andRichard Wolfbuilds off a longstanding relationship between the two companies associated...
PR Newswire
15/07/2024

Organic growth of 20% of the revenue as of June 24

Press release Ecully, July 11, 2023 – 6 p.m. First-half 2023 revenue of €5.4 million (+75%)Continued ramp-up of Distimp productsStrong sales growth in EuropeIn thousands of eurosUnaudited data 20232022 % change2023/2022Q1 revenue2,399 1,342 +79%Q2 revenue3,033 1,770 +71% H1 revenue 5,4323,113+75% Spineway's total revenue for the first half of 2023 was €5.4 million, up 75% compared with the first half...
Nasdaq GlobeNewswire
15/07/2024

EssilorLuxottica: Second-Quarter and First-Half 2024 Results Conference Call…

Second-Quarter and First-Half 2024 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our Second-Quarter and First-Half 2024 Results Conference Call on: Thursday, July 25, 2024, at 6:30 pm CEST Dial-in telephone access:If you wish to dial into the...
Nasdaq GlobeNewswire
15/07/2024

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of June 30, 2024(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Charenton-le-Pont, France (July 15, 2024 - 6:00 pm)– As of June 30, 2024, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks...
Nasdaq GlobeNewswire
15/07/2024

Polyglycolic Acid Market Size to Grow USD Million by 2030 at a CAGR of 23.9% |…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-14Q8921/Global_Polyglycolic_Acid_Market Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-14Q8921/Global_Polyglycolic_Acid_Market Major Factors Driving the Growth of Polyglycolic Acid Market: The market for polyglycolic acid (PGA) is expected to expand significantly because of its growing use in a number of sectors, including packaging, shale gas extraction, and medicine. PGA is frequently...
PR Newswire
15/07/2024

Exosome Isolation Market Set for Robust Growth to US$ 1.2 Billion Through 2034…

Progress in technologies like next-generation sequencing (NGS), proteomics, and advanced microscopy is facilitating better characterization and understanding of exosomes, propelling their use in various applications. Exosomes are increasingly being integrated with liquid biopsy techniques for non-invasive cancer diagnostics and monitoring. This trend is expected to significantly drive market growth due to the rising adoption of liquid biopsies. Progress in technologies like next-generation...
PR Newswire
15/07/2024

Genotyping Assay Market Poised for 22.5% CAGR Growth to USD 285.3 Billion by…

Rising popularity of DTC genetic testing kits that allow consumers to access genetic information without the need for a healthcare provider, driving market growth. Development of automated and miniaturized genotyping platforms that offer high throughput and ease of use. Growing research focus on rare diseases, leading to the development of specialized genotyping assays for their detection and study. Expanding applications in agriculture for crop and livestock improvement, which could open new…
PR Newswire
15/07/2024

PausePoint Helps Employees and Professionals Prioritize Mental Health

Committed to helping modern workers avoid burnout and boost productivity, Pause Point integrates directly into daily calendars that often drive the rhythm and intensity of the modern workday. PausePoint serves as an integrated prompt that ensures that mental health is scheduled in the flow of scheduled Committed to helping modern workers avoid burnout and boost productivity, Pause Point integrates directly into daily calendars that often drive the rhythm and intensity of the modern workday...
PR Newswire
15/07/2024

Dental Equipment Market worth $9.3 Billion by 2029 driven by Specialized Dental…

Browse in-depth TOC on "Dental Equipment Market" Browse in-depth TOC on "Dental Equipment Market" 268 - Tables60 - Figures320 - Pages DENTSPLY SIRONA INC. (US): Leader in Dental Equipment Solutions DENTSPLY SIRONA Inc., based in the US, is a key player in the dental equipment market, offering innovative solutions and technologies. Their extensive product portfolio includes dental consumables and advanced digital equipment, supported by strong R&D investment and...
PR Newswire
15/07/2024

Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus…

Laboratory at Makerere University Walter Reed Project, where Sabin's Phase 2 Sudan ebolavirus vaccine clinical trial begins this month. WASHINGTON, July15, 2024(GLOBE NEWSWIRE) -- Sabin Vaccine Institute launched a Phase 2 clinical trial for its vaccine againstSudan ebolavirus,with healthy volunteers receiving the single-dose vaccine at Makerere University Walter Reed Project (MUWRP) in Uganda. There are currently no approved vaccines for this strain of ebolavirus, which saw...
Nasdaq GlobeNewswire
15/07/2024

Active Pharmaceutical Ingredients (API) Market to Surpass USD 351.81 Billion…

Download a detailed overview: Download a detailed overview: https://www.skyquestt.com/sample-request/active-pharmaceutical-ingredients-market Active Pharmaceutical Ingredients (API) Market Overview: Segments covered in Active Pharmaceutical Ingredients (API) Market are as follows: Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/active-pharmaceutical-ingredients-market Low Costs of Synthetic API Manufacturing is Pushing...
PR Newswire
15/07/2024

Transparency Market Research Inc. Forecasts Injectable Drug Delivery Market to…

The spurring incidences of patients affected due to chronic diseases are likely to affect the size of the competitive space. With the rising prevalence of diseases, the demand for relevant drugs, medicines, and medical assistance is expected to proliferate in the forecast period. The spurring incidences of patients affected due to chronic diseases are likely to affect the size of the competitive space. With the rising prevalence of diseases, the demand for relevant drugs, medicines, and…
PR Newswire
15/07/2024

Pharmaceutical Quality Management Systems Market to Be Worth $4.59 Billion by…

Pharmaceutical Quality Management Systems (QMS) are sets of procedures and practices that contribute to the quality of pharmaceutical products. Quality management systems facilitate regulatory requirements relevant to industries and companies. ICH Q10 and ISO 9001:2015 are some of the most important quality standards and guidelines for the pharmaceutical industry. Quality Management systems have positively impacted the global pharmaceutical market and brought about significant changes in the…
PR Newswire
15/07/2024
Altri  Comunicati